The current status of the use of palonosetron.

@article{Navari2013TheCS,
  title={The current status of the use of palonosetron.},
  author={Rudolph M. Navari},
  journal={Expert opinion on pharmacotherapy},
  year={2013},
  volume={14 10},
  pages={1281-4}
}
Chemotherapy-induced nausea and vomiting (CINV) is associated with a significant deterioration in the quality of life. The emetogenicity of the chemotherapeutic agents, repeated chemotherapy cycles, and patient characteristics (female gender, younger age, low alcohol consumption, history of motion sickness) are the major risk factors for CINV. Palonosetron, a second-generation 5-hydroxytryptamine 3 (5-HT3) receptor antagonist, has antiemetic activity at both central and gastrointestinal sites… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS